Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Feb 6;118(3):e1.
doi: 10.1038/bjc.2017.342. Epub 2017 Nov 16.

Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'

Isabel Bravo  1
Affiliations
Comment

Comment on 'Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study'

Isabel Bravo. Br J Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Comment in

Comment on

References

    1. Kollar L, Rengan R (2014) Stereotactic body radiotherapy. Semin Oncol 41(6): 776–789. - PubMed
    1. Lewis S, Porceddu S, Nakamura N, Palma D, Lo S, Hoskin P, Moghakani D, Chmura S, Steven J (2017) Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists. Am J Clin Oncol 40(4): 418–422. - PubMed
    1. Miralbell R, Roberts S, Zubizarreta E, Hendry J (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β=1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 82(1): e17–e24. - PubMed
    1. Ost P, Jereczek-Fossa B, As N, Zilli T, Muacevic A, Olivier K, Henderson D, Casamassima F, Orecchia R, Surgp A, Brown L, Tree A, Mirabell R, De Meerleer G (2016) Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol 69(1): 9–12. - PubMed
    1. Stevens D, Sooriakumaran P (2016) Oligometastatic prostate cancer. Curr Treat Options Oncol 17: 62. - PMC - PubMed